Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses
in patients with many different types of cancer; however, most patients who receive ICB …

Tumor-infiltrating dendritic cells (DCs) assume varied functional states that impact anti-tumor
immunity. To delineate the DC states associated with productive anti-tumor T cell immunity …

Developing strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …

The successful clinical application of immune checkpoint blockade (ICB) and chimeric
antigen receptor T cells (CAR-T) therapeutics has attracted extensive attention to …

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think
about cancer treatment. Even so, for most types of cancer, only a minority of patients …

Summary RNA N 6-methyladenosine (m 6 A) modification is implicated in cancer
progression. However, the impact of m 6 A on the antitumor effects of radiotherapy and the …

Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or
bacterial infection and induce host innate immune responses. The RLRs family comprises …

Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in
preclinical studies and in some patients with melanoma,–, but its efficacy in inducing …